Dokumentanzeige 

Zur Kurzanzeige

Título
Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data.
dc.contributor.authorCañueto Álvarez, Javier 
dc.contributor.authorMuñoz-Couselo, E
dc.contributor.authorCardona-Machado, C
dc.contributor.authorBecerril-Andrés, Sara
dc.contributor.authorMartín Vallejo, Francisco Javier 
dc.contributor.authorSerra-Guillén, C
dc.contributor.authorSoria, A
dc.contributor.authorSerrano-Domingo, J J
dc.contributor.authorOrtiz-Velez, C
dc.contributor.authorLostes, J
dc.contributor.authorGarcía-Castaño, A
dc.contributor.authorPuig, S
dc.contributor.authorFernández de Misa, R
dc.contributor.authorMedina, J
dc.contributor.authorAguado, C
dc.contributor.authorAyala de Miguel, P
dc.contributor.authorNavarro-Navarro, I
dc.contributor.authorMasferrer, E
dc.contributor.authorDelgado, M
dc.contributor.authorBellido-Hernández, L
dc.contributor.authorSanmartin, O
dc.date.accessioned2025-12-15T08:56:54Z
dc.date.available2025-12-15T08:56:54Z
dc.date.issued2024-08
dc.identifier.citationCañueto, J., Muñoz-Couselo, E., Cardona-Machado, C., Becerril-Andrés, S., Martín-Vallejo, J., Serra-Guillén, C., Soria, A., Serrano-Domingo, J.J., Ortiz-Velez, C., Lostes, J., García-Castaño, A., Puig, S., Fernández de Misa, R., Medina, J., Aguado, C., Ayala de Miguel, P., Navarro-Navarro, I., Masferrer, E., Delgado, M., Bellido-Hernández, L. and Sanmartin, O. (2024), Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data. J Eur Acad Dermatol Venereol, 38: e666-e670. https://doi.org/10.1111/jdv.19821es_ES
dc.identifier.issn0926-9959
dc.identifier.urihttp://hdl.handle.net/10366/168278
dc.description.abstract[EN]In this retrospective, observational, multicentre study,we searched for patients who were treated with systemic cemiplimab for advanced CSCC from 12 different Spanish centres (from 2019 to 2022). Patient demographics, primary tumour clinical and histological features, and other relevant medical history traits such as immunosuppression were collected.es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCemiplimabes_ES
dc.subjectCutaneous squamous cell carcinomaes_ES
dc.subjectMulticentre real-world retrospective studyes_ES
dc.subject.meshAged *
dc.subject.meshSkin Neoplasms *
dc.subject.meshCarcinoma *
dc.subject.meshAntibodies *
dc.subject.meshTreatment Outcome *
dc.subject.meshHumans *
dc.subject.meshAntineoplastic Agents *
dc.subject.meshMiddle Aged *
dc.subject.meshRetrospective Studies *
dc.titleEfficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data.es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1111/jdv.19821es_ES
dc.identifier.doi10.1111/jdv.19821
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid38308557
dc.identifier.essn1468-3083
dc.journal.titleJournal of the European Academy of Dermatology and Venereology : JEADVes_ES
dc.volume.number38es_ES
dc.issue.number8es_ES
dc.page.initiale666es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsresultado del tratamiento *
dc.subject.decshumanos *
dc.subject.decsantineoplásicos *
dc.subject.decsanciano *
dc.subject.decscarcinoma *
dc.subject.decsmediana edad *
dc.subject.decsestudios retrospectivos *
dc.subject.decsneoplasias cutáneas *
dc.subject.decsanticuerpos *


Dateien zu dieser Ressource

Thumbnail
Name:
Acad Dermatol Venereol - 2024 - ...
Größe:
121.8Kb
Format:
PDF
Öffnen

Das Dokument erscheint in:

Zur Kurzanzeige

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: Attribution-NonCommercial-NoDerivatives 4.0 Internacional